21Aug 2024
Esketamine Boosts Neurotransmitter Levels and Reduces Postpartum Depression Symptoms

Esketamine Boosts Neurotransmitter Levels and Reduces Postpartum Depression Symptoms

A study evaluated the effects of intravenous esketamine on neurotransmitter levels and postpartum depression. Three hundred fifteen patients with postpartum depression were randomized to receive either 0.25 mg/kg esketamine or saline over 40 minutes. Serum levels of neurotransmitters—5-hydroxytryptamine (5-HT), dopamine (DA), noradrenaline (NE), and brain-derived neurotrophic factor (BDNF)—were measured before and on the third day after treatment. Esketamine significantly increased 5-HT, DA, and BDNF levels and reduced Edinburgh Postnatal Depression Scale (EPDS) scores on day 3. Adverse events were similar between the esketamine and control groups. Esketamine proved effective in improving postpartum depressive symptoms by modulating neurotransmitter levels in the short term.

  • #gynaecology - ivf

Like

Save

Share